Search Results for: FGFR1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 1
  • mTORC1-mediated signalling
  • Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
Novel NRG1 neuregulin 1
  • Signaling by ERBB2
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PI3K events in ERBB4 signaling
  • SHC1 events in ERBB4 signaling
  • Nuclear signaling by ERBB4
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • Long-term potentiation
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 TMD/JMD mutants
Novel OR51B4 olfactory receptor family 51 subfamily B member 4
  • Olfactory Signaling Pathway
Novel PPP2CB protein phosphatase 2 catalytic subunit beta
  • Inhibition of replication initiation of damaged DNA by RB1/E2F1
  • Spry regulation of FGF signaling
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Integration of energy metabolism
  • PP2A-mediated dephosphorylation of key metabolic factors
  • DARPP-32 events
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • ERK/MAPK targets
  • ERKs are inactivated
  • MASTL Facilitates Mitotic Progression
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • CTLA4 inhibitory signaling
  • Platelet sensitization by LDL
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Signaling by GSK3beta mutants
  • S33 mutants of beta-catenin aren't phosphorylated
  • S37 mutants of beta-catenin aren't phosphorylated
  • S45 mutants of beta-catenin aren't phosphorylated
  • T41 mutants of beta-catenin aren't phosphorylated
  • APC truncation mutants have impaired AXIN binding
  • AXIN missense mutants destabilize the destruction complex
  • Truncations of AMER1 destabilize the destruction complex
  • RHO GTPases Activate Formins
  • RAF activation
  • Negative regulation of MAPK pathway
  • Regulation of TP53 Degradation
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Mitotic Prometaphase
  • Cyclin D associated events in G1
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Regulation of glycolysis by fructose 2,6-bisphosphate metabolism
  • EML4 and NUDC in mitotic spindle formation
  • Vitamin E
Novel SHB SH2 domain containing adaptor protein B
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
Novel TPMT thiopurine S-methyltransferase
  • Methylation
  • Defective TPMT causes Thiopurine S-methyltransferase deficiency (TPMT deficiency)
  • Olsalazine
  • Thiopurine S-methyltransferase deficiency (TPMT deficiency)
Novel ZFYVE1 zinc finger FYVE-type containing 1
BNIP2 BCL2 interacting protein 2
  • Myogenesis
  • Myogenesis
CDH1 cadherin 1
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Integrin cell surface interactions
  • Apoptotic cleavage of cell adhesion proteins
  • Adherens junctions interactions
  • RHO GTPases activate IQGAPs
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • Gastric cancer
  • Penile cancer
  • Nasopharyngeal cancer
  • Breast cancer
  • Hepatocellular carcinoma
  • Thyroid cancer
CREBBP CREB binding protein
  • Regulation of gene expression by Hypoxia-inducible Factor
  • RORA activates gene expression
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • PPARA activates gene expression
  • PPARA activates gene expression
  • Formation of the beta-catenin:TCF transactivating complex
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Transcriptional activation of mitochondrial biogenesis
  • Activation of gene expression by SREBF (SREBP)
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • HATs acetylate histones
  • Attenuation phase
  • Notch-HLH transcription pathway
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • SUMOylation of transcription cofactors
  • Regulation of lipid metabolism by PPARalpha
  • Circadian Clock
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • CD209 (DC-SIGN) signaling
  • TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
  • Activation of the TFAP2 (AP-2) family of transcription factors
  • RUNX1 regulates transcription of genes involved in differentiation of myeloid cells
  • RUNX3 regulates NOTCH signaling
  • RUNX3 regulates NOTCH signaling
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Estrogen-dependent gene expression
  • TRAF3-dependent IRF activation pathway
  • TRAF6 mediated IRF7 activation
  • FOXO-mediated transcription of cell death genes
  • Regulation of FOXO transcriptional activity by acetylation
  • Regulation of FOXO transcriptional activity by acetylation
  • 9-ACETYL-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-1-ONE
  • Rubinstein-Taybi syndrome
CRK CRK proto-oncogene, adaptor protein
  • ARMS-mediated activation
  • ARMS-mediated activation
  • Downstream signal transduction
  • Regulation of actin dynamics for phagocytic cup formation
  • p130Cas linkage to MAPK signaling for integrins
  • VEGFA-VEGFR2 Pathway
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • Regulation of signaling by CBL
  • FCGR3A-mediated phagocytosis
CTPS2 CTP synthase 2
  • Interconversion of nucleotide di- and triphosphates
EPHA4 EPH receptor A4
  • EPH-Ephrin signaling
  • EPH-Ephrin signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • EPH-ephrin mediated repulsion of cells
  • EPH-ephrin mediated repulsion of cells
  • Fostamatinib
ERBB2 erb-b2 receptor tyrosine kinase 2
  • Signaling by ERBB2
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D induced cell migration and growth-cone collapse
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Trastuzumab
  • Lapatinib
  • IGN311
  • Trastuzumab emtansine
  • Varlitinib
  • AV-412
  • Pertuzumab
  • Afatinib
  • Tucatinib
  • Tesevatinib
  • Fostamatinib
  • Brigatinib
  • Margetuximab
  • Zanubrutinib
  • Choriocarcinoma
  • Pancreatic cancer
  • Gastric cancer
  • Bladder cancer
  • Endometrial Cancer
  • Ovarian cancer
  • Cholangiocarcinoma
  • Breast cancer
  • Cervical cancer
ERBB3 erb-b2 receptor tyrosine kinase 3
  • Tucatinib
  • Lethal congenital contractural syndrome (LCCS)
  • Type I diabetes mellitus
FBXO7 F-box protein 7
  • Neddylation
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Parkinson's disease (PD)
FDPS farnesyl diphosphate synthase
  • Cholesterol biosynthesis
  • Activation of gene expression by SREBF (SREBP)
  • Pamidronic acid
  • Zoledronic acid
  • Alendronic acid
  • Ibandronate
  • Risedronic acid
  • Dimethylallyl Diphosphate
  • Isopentyl Pyrophosphate
  • Geranyl Diphosphate
  • ISOPENTENYL PYROPHOSPHATE
  • Incadronic acid
  • Minodronic acid
  • Farnesyl diphosphate
  • Geranylgeranyl diphosphate
FGF1 fibroblast growth factor 1
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by activated point mutants of FGFR1
  • Signaling by activated point mutants of FGFR3
  • FGFR4 ligand binding and activation
  • FGFR1b ligand binding and activation
  • FGFR3b ligand binding and activation
  • FGFR3c ligand binding and activation
  • FGFR1c ligand binding and activation
  • FGFR2c ligand binding and activation
  • FGFR2b ligand binding and activation
  • FGFR3 mutant receptor activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR1 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by FGFR2 IIIa TM
  • Signaling by FGFR3 point mutants in cancer
  • Pentosan polysulfate
  • Amlexanox
  • Heparin
  • Sucrosofate
  • Formic acid
  • O2-Sulfo-Glucuronic Acid
  • N,O6-Disulfo-Glucosamine
  • Naphthalene Trisulfonate
  • Pazopanib
  • 5-aminonaphthalene-2-sulfonic acid
  • Foreskin fibroblast (neonatal)
  • Foreskin keratinocyte (neonatal)
FGF10 fibroblast growth factor 10
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • FGFR1b ligand binding and activation
  • FGFR2b ligand binding and activation
  • Activated point mutants of FGFR2
  • Regulation of gene expression in early pancreatic precursor cells
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Signaling by FGFR2 in disease
  • FGFRL1 modulation of FGFR1 signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Aplasia of lacrimal and salivary glands
  • Lacrimo-auriculo-dento-digital syndrome (LADD); Levy-Hollister syndrome
FGF17 fibroblast growth factor 17

Page 1 out of 4 pages